The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

The BREELIB nebulizer was developed for iloprost to reduce inhalation times for patients with pulmonary arterial hypertension (PAH). This multicenter, randomized, unblinded, four-part study compared inhalation time, pharmacokinetics, and acute tolerability of iloprost 5 µg at mouthpiece delivered vi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pulm Circ
Main Authors: Gessler, Tobias, Ghofrani, Hossein-Ardeschir, Held, Matthias, Klose, Hans, Leuchte, Hanno, Olschewski, Horst, Rosenkranz, Stephan, Fels, Lueder, Li, Na, Ren, Dawn, Kaiser, Andreas, Schultze-Mosgau, Marcus-Hillert, Müllinger, Bernhard, Rohde, Beate, Seeger, Werner
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2017
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467944/
https://ncbi.nlm.nih.gov/pubmed/28597762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217706691
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares